Andrew Guggenhime, PRESIDENT AND CFO at Vaxcyte, Inc. (PCVX), sold 16,000 shares at $86.08 ($1.4M) on 2025-01-21, disclosed to the SEC on 2025-01-22.
Scheduled sale ($1.4M) by PRESIDENT AND CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $86.08 | 5,318 | $458K | 33.1% |
| 2 | $86.08 | 5,318 | $458K | 33.1% |
| 3 | $87.25 | 1,999 | $174K | 12.6% |
| 4 | $87.25 | 1,999 | $174K | 12.6% |
| 5 | $87.70 | 683 | $60K | 4.3% |
| 6 | $87.70 | 683 |
| $60K |
| 4.3% |
| Total | $86.51 avg | 16,000 | $1.4M | 100% |
| Filing → |
| PCVX | SELL | 2026-06-18 | $530K | — | Filing → |
| PCVX | SELL | 2025-02-19 | $1.3M | — | Filing → |
| PCVX | SELL | 2024-12-19 | $1.4M | — | Filing → |